Valuation: TScan Therapeutics, Inc.

Market Cap 52.03M 45.04M 42.1M 38.48M 72.51M 4.96B 73.65M 494M 194M 2.48B 195M 191M 8.27B P/E 2026 *
-0.91x
P/E 2027 * -0.86x
Enterprise Value -46.83M -40.54M -37.9M -34.64M -65.27M -4.47B -66.29M -444M -174M -2.23B -176M -172M -7.44B EV / Sales 2026 *
-6.2x
EV / Sales 2027 * -2.91x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
30/07 Tscan Therapeutics Doses First Patient in Phase 3 ALLOHA-2 Trial Evaluating TSC-101 in Patients with Heme Malignancies CI
22/06 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
22/06 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
04/06 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
06/05 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02/04 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
04/03 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
27/02 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
27/02 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
19/12 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
07/12 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
15/11 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
12/11 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
1 day-3.17%
1 week+6.47%
Current month+3.66%
1 month-29.34%
3 months-34.73%
6 months-22.71%
Current year-22.98%
1 week 0.72
Extreme 0.716
0.8
1 month 0.72
Extreme 0.716
1.1
Current year 0.72
Extreme 0.716
1.47
1 year 0.72
Extreme 0.716
2.57
3 years 0.72
Extreme 0.716
9.69
5 years 0.72
Extreme 0.716
14.71
10 years 0.72
Extreme 0.716
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Free

General Counsel

350,000 0.6670%
20/1/26 Free

Chief Executive Officer

1,165,000 2.2203%
20/1/26 Free

Chief Technology Officer

420,000 0.8004%
Change 5-day change 1-year change 3-year change Capi.($)
-3.67%+6.47%-52.16%-63.32% 52.03M
+4.21%+25.62%+77.96%+111.62% 68.12B
+0.50%+2.95%+34.94%+69.77% 55.18B
+2.78%+35.25%+17.95%+486.05% 28.63B
+0.57%+19.05%+57.08%+5.18% 23.99B
-0.93%+1.08%-14.65%-11.58% 23.53B
-0.35%+7.18%+44.14%-22.28% 18.45B
-2.04%+9.24%+31.14%+650.71% 16.44B
+7.26%+25.47%+221.03%+383.67% 15.83B
-2.05%-4.40%+40.70%+148.87% 13.4B
Average +0.57%+9.71%+45.81%+175.87% 26.36B
Weighted average by Cap. +1.55%+11.35%+53.66%+165.28%

Financials

2026 *2027 *
Net sales 7.56M 6.54M 6.12M 5.59M 10.53M 721M 10.7M 71.71M 28.14M 361M 28.38M 27.76M 1.2B 7.81M 6.76M 6.32M 5.77M 10.88M 745M 11.05M 74.08M 29.07M 372M 29.31M 28.68M 1.24B
Net income -115M -99.62M -93.11M -85.1M -160M -10.97B -163M -1.09B -428M -5.49B -432M -423M -18.29B -125M -108M -101M -92.31M -174M -11.9B -177M -1.18B -465M -5.96B -469M -458M -19.83B
Net Debt -98.87M -85.59M -80M -73.12M -138M -9.43B -140M -938M -368M -4.72B -371M -363M -15.71B -74.76M -64.72M -60.49M -55.29M -104M -7.13B -106M -709M -278M -3.57B -281M -275M -11.88B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
11/08/26 USD 0.7670 -3.67% 456,473
07/08/26 USD 0.7962 +4.32% 336,330
06/08/26 USD 0.7632 -2.15% 129,861
05/08/26 USD 0.7800 +5.91% 298,715
04/08/26 USD 0.7365 +1.81% 796,346
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7962USD
Average target price
6.000USD
Spread / Average Target
+653.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock